20 MANAGEMENT'S DISCUSSION AND ANALYSIS
This section describes material changes in the results of operations for
Allegiance Corporation ("Allegiance" or the "company") during the three years
ended December 31, 1997, and the company's financial condition at that date.
Material trends are discussed to the extent known and considered relevant.
OVERVIEW
On September 30, 1996 (the "Distribution Date"), Baxter International Inc.
("Baxter") and its subsidiaries transferred to Allegiance and its subsidiaries
their U.S. health-care distribution business, surgical and respiratory therapy
business and health-care cost-saving business, as well as certain foreign
operations (the "Allegiance Business") in connection with a spin-off of the
Allegiance Business by Baxter. The spin-off occurred on the Distribution Date
through a distribution of Allegiance common stock to Baxter stockholders.
Allegiance operates in a single industry segment as a leading provider of
health-care products and services. Through its nationwide distribution network,
Allegiance distributes a wide offering of medical, surgical and laboratory
products, including its self-manufactured surgical and respiratory therapy
products, to hospitals, doctors' offices, surgery centers, home-care companies,
post-acute-care facilities and other caregivers outside the hospital. Allegiance
also provides integrated cost-saving services to its health-care customers
through inventory-management programs, customized packaging, and various
consulting services. The delivery of such a broad array of products and services
requires focused investments in cost-saving services, information systems, and
manufacturing and distribution efficiencies.
Health-care spending in the United States and abroad continues to rise. At the
same time, reimbursement for health-care services is being ratcheted down by
insurers and governments. As a result, hospitals are under increasing pressure
to contain costs while providing high-quality care to growing numbers of
patients. These forces, along with new medical technologies, are causing a shift
in health-care services to outpatient settings such as surgery centers, doctors'
offices and others. Demand for health care is expected to grow faster in the
years to come as the elderly segment of the population grows to record levels.
These forces increasingly shape the demand for, and supply of, medical care.
Many private health-care payers provide incentives for consumers to seek lower
cost care. Many corporations' employee health plans provide financial incentives
for patients to use the most cost-effective forms of treatment (managed care
programs, such as health maintenance organizations, are common), and physicians
are being encouraged to provide more cost-effective treatments. The fundamental
changes that have occurred in the U.S. health-care system in recent years,
including customer and competitor consolidations and cost-containment efforts,
are expected to continue.
Hospitals and other providers are expected to continue to push for greater
efficiency, reduced excess capacity and lower costs. Allegiance management
believes this presents an opportunity for the company, which is well positioned
to help health-care providers enhance their competitiveness and to provide
products to all sites of care. Management believes it can help health-care
providers achieve savings by automating supply-ordering procedures; optimizing
distribution networks; improving utilization, materials management and labor
productivity; achieving economies through product and procedure standardization;
and performing certain non-clinical services on an outsourced basis. Allegiance
further believes its strategy of providing superior service to its customers and
achieving the best overall cost in the delivery of health-care products and
services is compatible with any anticipated realignment of the U.S. health-care
system.
Allegiance Corporation 1997 Annual Report
MANAGEMENT'S DISCUSSION AND ANALYSIS 21
Results of Operations
DIVESTED BUSINESSES
Allegiance's historical results of operations in 1995 include revenues and
expenses related to certain divested businesses: the Industrial and Life
Sciences division ("Industrial") that was sold in September 1995 and the
diagnostics manufacturing businesses that were sold in December 1994. The
discussion on results of operations that follows includes comparisons to 1995
that exclude amounts related to these divestitures. Refer to Note 1 for 1995
financial data that excludes revenues and expenses associated with these
businesses.
SALES PERCENTAGE
increase (decrease)
years ended December 31 (in millions, except percentages) 1997 1996 1995 1997 1996
- ------------------------------------------------------------------------------------------------------------------
Geographic regions
United States $4,061.1 $4,097.0 $4,283.7 (0.9%) (4.4%)
International 289.7 290.2 291.3 (0.2) (0.4)
- ------------------------------------------------------------------------------------------------------------------
Total net sales $4,350.8 $4,387.2 $4,575.0 (0.8%) (4.1%)
- ------------------------------------------------------------------------------------------------------------------
Distributed products $2,742.7 $2,791.2 $3,003.5 (1.7%) (7.1%)
Self-manufactured products 1,608.1 1,596.0 1,571.5 0.8 1.6
- ------------------------------------------------------------------------------------------------------------------
Total net sales $4,350.8 $4,387.2 $4,575.0 (0.8%) (4.1%)
- ------------------------------------------------------------------------------------------------------------------
The decline in net sales of Allegiance's domestic and distributed products in
both 1997 and 1996 resulted principally from planned reductions in sales of
lower-margin, distributed products in the United States.
International sales volume was generally flat in all years presented. In 1997,
Allegiance was able to offset adverse foreign-exchange rates and lower sales in
European markets with incremental sales from a new venture in Canada, Source
Medical Corporation (See Note 6). During 1997 and 1996, international sales
comparisons were impacted unfavorably by Allegiance's selling arrangements in
some international markets. When Allegiance was part of Baxter, it marketed
products directly to customers. Since becoming an independent public company,
Allegiance sells products through Baxter as a distributor. This change reduced
Allegiance's direct selling influence and resulted in lower sales volume.
Growing its international business remains a strategic priority for Allegiance.
The increase in sales of self-manufactured products in 1997 resulted from the
favorable impact of a major agreement with Premier, Inc. ("Premier"), discussed
below, and an increase in cost-saving agreements (which generally result in
favorable growth of higher-margin, self-manufactured products), offset partially
by pricing pressures. Sales in 1996 also benefited from an increase in cost-
saving agreements, as well as an initial stocking order following an agreement
signed with General Medical Corporation, also offset partially by pricing
pressures. In both 1997 and 1996, domestic sales growth of self-manufactured
products was offset slightly by sales declines in international markets.
In November 1996, Allegiance signed a seven-year agreement with Premier to
supply its member hospitals with certain surgical and respiratory therapy
products. This agreement, which began to impact sales favorably in late 1997,
will continue to produce sales growth in 1998. Refer to Note 16 for a discussion
of customers who represent a significant amount of the company's sales over the
last three years, and the risks associated with potential loss of this business
in the future.
Allegiance Corporation 1997 Annual Report
22 MANAGEMENT'S DISCUSSION AND ANALYSIS
GROSS MARGIN AND EXPENSE RATIOS
years ended December 31 (as a percentage of sales) 1997 1996 1995
- -----------------------------------------------------------------------------
Gross margin 20.9% 20.7% 20.8%
Selling, general and administrative expenses 15.1 15.3 15.2
- -----------------------------------------------------------------------------
The company has succeeded in maintaining a relatively flat gross margin since
1995, despite continued pricing pressure on its self-manufactured products. The
company has generally been able to offset this pressure with cost efficiencies
and a more profitable sales mix. In 1997, the increase in sales of self-
manufactured products, and planned reductions in lower-margin distributed
products, combined to more than offset pricing pressures from the Premier
contract and the general marketplace. Allegiance plans to continue its efforts
to maintain its gross margin rate by offsetting pricing pressures with
manufacturing and other cost efficiencies, boosting sales of cost-saving
services, managing its sales mix more effectively, and, when possible,
instituting price increases.
The company succeeded in reducing selling, general and administrative expenses
on an absolute basis by $13.0 million and as a percentage of sales in 1997
principally by reducing headcount through attrition, managing benefit costs and
implementing overall expense-control initiatives in both current and prior
periods. Total selling, general and administrative expenses were reduced by
$22.8 million in 1996 compared to 1995, excluding the divested businesses
discussed previously. Such costs as a percentage of sales, however, increased
slightly as the timing of expense-reduction initiatives lagged the planned
reduction in lower-margin product sales discussed earlier.
GOODWILL WRITE-DOWN AND OTHER NON-RECURRING ITEMS
In the fourth quarter of 1996, the company changed its method of assessing
goodwill impairment, resulting in a charge to operations of $550.0 million and a
reduction in goodwill amortization of $18.9 million in 1997 and $4.7 million in
1996. Refer to Note 2 for a discussion of the company's new policy. Allegiance
also incurred $95.5 million of other non-recurring costs in the 1996 fourth
quarter. Refer to Note 4 for a discussion of various items included in this
amount.
RESTRUCTURING PROGRAM
In November 1993, Baxter initiated a restructuring program to improve
shareholder value and reduce costs. These strategic actions were designed in
part to make the Allegiance Business more efficient and responsive in addressing
the changes occurring in the U.S. health-care system. See Note 5 for more
information, including the cash and noncash utilization of the reserves and
headcount reductions to date.
Allegiance realized direct savings in manufacturing and administrative costs
from this program of approximately $170 million in 1997, $125 million in 1996,
and $95 million in 1995. Management believes that the program is on target to
achieve anticipated savings exceeding $175 million in 1998. The company
anticipates that these savings will continue to help offset potential gross
margin erosion and investments in cost-saving and other initiatives. Management
further believes that its remaining restructuring reserves are adequate to
complete the actions contemplated by the restructuring program and that future
cash expenditures related to the program would be funded from cash generated
from operations.
Allegiance Corporation 1997 Annual Report
MANAGEMENT'S DISCUSSION AND ANALYSIS 23
BENEFIT CURTAILMENT GAINS
Non-recurring gains of $35.9 million in 1996 are associated with the curtailment
of Baxter-sponsored benefit plans and are discussed in Note 12.
INTEREST EXPENSE
The increase in interest expense in 1997 resulted from a full year of borrowings
in 1997 compared to only fourth-quarter borrowings in 1996. Prior to September
30, 1996, Allegiance participated in a centralized cash-management program
administered by Baxter. No interest was charged to Allegiance.
OTHER INCOME AND EXPENSE
The company currently has foreign-currency forward and option contracts that
have been combined to hedge a portion of anticipated production costs expected
to be denominated in foreign currencies. The company recognizes realized and
unrealized gains and losses on these contracts in the period in which the change
occurs. Other income and expense for 1997 included $11.6 million of expense
related to these foreign-currency contracts.
Also included in other income and expense in 1997 was $5.9 million of income
associated with the reversal of excess reserves for facility shutdowns related
to the Industrial divestiture. These shutdown programs, substantially completed
in 1997, were finalized at a lower cost than originally anticipated.
The remaining change in other income and expense for 1997 versus 1996 was caused
by unfavorable foreign-exchange rates and losses related to certain equity
investments.
Other income for 1995, excluding the divested businesses discussed previously,
consisted primarily of net gains associated with the disposal or discontinuance
of minor, non-strategic businesses.
PRETAX INCOME Percentage
increase (decrease)
years ended December 31 (in millions, except percentages) 1997 1996 1995 1997 1996
- -------------------------------------------------------------------------------------------------------------
Pretax income (loss) $143.0 $(427.9) $245.3 n/a n/a
Adjust for non-recurring items (1) - 609.6 (37.3) - -
Adjust for interest expense 67.5 18.9 - - -
- -------------------------------------------------------------------------------------------------------------
Adjusted pretax income $210.5 $ 200.6 $208.0 4.9% (3.6%)
- -------------------------------------------------------------------------------------------------------------
Adjusted pretax income as a percentage of sales 4.8% 4.6% 4.5% - -
- -------------------------------------------------------------------------------------------------------------
(1) The 1996 non-recurring adjustments include the goodwill write-down, benefit
curtailment gains and other non-recurring items discussed previously. The 1995
non-recurring adjustments reflect net gains associated with the disposal or
discontinuance of minor, non-strategic businesses.
Allegiance Corporation 1997 Annual Report
24 MANAGEMENT'S DISCUSSION AND ANALYSIS
Pretax income as a percentage of sales increased in 1997 over 1996, excluding
the impact of the goodwill write-down, interest expense and the non-recurring
gains from curtailment of certain benefit plans, all discussed previously.
Contributing to the increase were an improved gross margin rate and reductions
in selling, general and administrative expenses in 1997. Adjusted pretax income
as a percentage of sales was relatively consistent between 1996 and 1995.
INCOME TAXES
years ended December 31 (in millions, except percentages) 1997 1996 1995
- ---------------------------------------------------------------------------------------
Income tax expense $52.1 $49.8 $94.4
Tax rate 36.4% n/a 38.5%
Adjust for non-recurring items (1) - 32.7 -
- ---------------------------------------------------------------------------------------
Adjusted income tax expense $52.1 $82.5 $94.4
Tax rate 36.4% 37.9% 38.5%
- ---------------------------------------------------------------------------------------
(1) Amount represents the tax benefit associated with the 1996 non-recurring
adjustments discussed previously.
The 1997 tax rate was lower than the 1996 adjusted tax rate, due principally to
the positive impact on earnings of lower goodwill amortization, which is a non-
taxable item. The positive impact of goodwill amortization in 1997, however, was
offset partially by a larger proportion of earnings from higher tax
jurisdictions. The adjusted rate in 1996 was lower than the 1995 rate (which
excludes the divested businesses discussed previously) because of lower goodwill
amortization in 1996.
IMPACT OF INFLATION
In recent years, general inflationary trends have led to higher labor and
material costs for Allegiance. While not related directly to inflation,
Allegiance's revenue base in recent years has been affected adversely by lower
average selling prices on certain products. Changes in Medicare reimbursement
regulations, economic pressures in the U.S. hospital marketplace and increased
competition in certain product lines were the main factors. There is little
correlation between general inflation rates and Allegiance's pricing levels.
Management expects these market dynamics to continue.
YEAR 2000 ISSUES
Allegiance is currently implementing enterprise-wide software that will replace
our financial and business legacy systems. This software, which is Year 2000
compliant, will be in place company-wide by early 1999. All other system
replacements or upgrades will be completed in 1999. The company does not expect
the impact of internal Year 2000 issues to be material to the company's
business, operations or financial condition. Management is currently attempting
to assess how Year 2000 issues at its suppliers and customers could impact the
company's business. Based upon current information, the company does not expect
any widespread supplier and customer non-compliance that could have a material
adverse effect.
ADOPTION OF NEW ACCOUNTING STANDARDS
The company adopted Statement of Financial Accounting Standards (SFAS) No. 128,
"Earnings Per Share," at December 31, 1997. SFAS No. 128 requires presentation
on the face of the income statement of both basic and diluted earnings per
share. See Note 2.
Allegiance Corporation 1997 Annual Report
MANAGEMENT'S DISCUSSION AND ANALYSIS 25
Liquidity and Capital Resources
Allegiance's current assets exceeded current liabilities by $548.8 million at
December 31, 1997, versus an excess of $637.4 million at December 31, 1996.
Current assets at December 31, 1997, included accounts, notes and other current
receivables of $528.1 million and inventories of $586.9 million. These sources
of liquidity are convertible into cash over a relatively short period of time
and, thus, could be available to help Allegiance satisfy normal operating cash
requirements.
The company intends to fund its short- and long-term obligations as they mature
through cash flow from operations, existing credit facilities or issuance of
debt or equity. Management believes the company has credit facilities adequate
to support ongoing operational, capital, restructuring and litigation
requirements. Beyond that, Allegiance believes it has sufficient financial
flexibility to attract long-term capital on acceptable terms as may be needed to
support its growth objectives. To meet its net financing requirements in 1997,
the company borrowed from its various credit facilities, as required. Refer to
Note 7 for more information about the company's borrowings under credit
facilities and outstanding debt.
years ended December 31 (in millions)
(brackets denote cash outflows) 1997 1996 1995
- ----------------------------------------------------------------------------
Cash flow provided by operations as stated
in the company's Consolidated
Statements of Cash Flows $327.6 $ 317.1 $ 253.3
Capital expenditures (81.3) (102.5) (111.9)
Common stock cash dividends (22.7) - -
- ----------------------------------------------------------------------------
"Free cash flow" $223.6 $ 214.6 $ 141.4
- ----------------------------------------------------------------------------
The increase in cash flow from operations in 1997 resulted from improved
earnings and balance sheet management -- primarily inventories and accounts
receivable. The increase in cash flow from operations in 1996 resulted from
improved management of inventories and accounts payable.
Management emphasizes "free cash flow" as an internal measure of operating cash
flow after capital expenditures and dividends as reconciled in the table above.
Management's objective is to maximize "free cash flow," and incentive
compensation programs throughout the company include emphasis on management of
working capital and "free cash flow" targets. The "free cash flow" generated
during 1997 helped to fund $60.9 million in acquisitions and $35.8 million in
stock repurchases, and to pay down $210.7 million of long-term debt. The
company's long-term debt as a percentage of total capital declined from 57.2
percent at December 31, 1996, to 49.0 percent at December 31, 1997.
Capital expenditures consisted principally of improvements to existing
facilities, systems upgrades, productivity enhancing equipment and other cost-
reduction projects. Allegiance management expects 1998 investments in capital
expenditures to remain at levels consistent with 1997.
In 1997, the board of directors declared four consecutive quarterly dividends on
the company's common stock of $0.10 per share (annualized rate of $0.40 per
share).
Allegiance Corporation 1997 Annual Report
26 MANAGEMENT'S DISCUSSION AND ANALYSIS
Acquisitions of $60.9 million in 1997, $23.8 million in 1996 and $5.4 million in
1995 were consistent with Allegiance's strategic direction and were made to
broaden product lines and service offerings or expand market coverage. See Note
6 for additional information related to the company's acquisitions.
Proceeds from asset dispositions of $35.2 million in 1997 related to the sale of
miscellaneous facilities and divestitures of minor investments inconsistent with
Allegiance's strategic direction. Divested investments in 1997 included
MedManagement, L.L.C., which is discussed in Note 6. The net use of cash of
$11.2 million in 1996 related to cash payments from the settlement of certain
programs associated with the divestitures of the Industrial and diagnostics
manufacturing businesses. The proceeds in 1995 of $626.0 million related to the
Industrial divestiture and the collection of notes receivable related to the
divestiture of the diagnostics manufacturing businesses.
Refer to Note 11 for a discussion of the $54.8 million in cash received in May
1997 from employees related to the company's Shared Investment Plan and the
$35.8 million spent to repurchase Allegiance common stock under a program
authorized by the company's board of directors in November 1997.
Litigation
Upon the Distribution, Allegiance assumed the defense of litigation involving
claims related to the Allegiance Business, including certain claims of alleged
personal injuries as a result of allergies to natural rubber latex gloves. See
Note 15. The company is a defendant in, or has assumed the defense of, a number
of other claims, investigations and lawsuits. Upon resolution of any of the
uncertainties described in Note 15, the company may incur charges in excess of
presently established reserves. Based on the advice of counsel, management does
not believe the outcome of these matters, individually or in the aggregate, will
have a material adverse effect on Allegiance's overall business, cash flow,
results of operations or financial condition.
- --------------------------------------------------------------------------------
FORWARD-LOOKING STATEMENTS
Certain statements in this discussion constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements indicating the company "plans," "expects," "estimates" or "believes"
are forward-looking statements that involve known and unknown risks, including,
but not limited to, general economic and business conditions, changing trends in
the health-care industry and customer profiles, competition, changes in
governmental regulations, and unfavorable foreign-currency fluctuations.
Although Allegiance believes its expectations with respect to the forward-
looking statements are based upon reasonable assumptions within the bounds of
its knowledge of its business and operations, there can be no assurance that
actual results, performance or achievements of Allegiance will not differ
materially from any future results, performance or achievements expressed or
implied by such forward-looking statements. In accordance with "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995, Allegiance
provides cautionary statements, detailed in Securities and Exchange Commission
filings, including, without limitation, the company's Form 10-K and 10-Qs, which
identify specific factors that would cause actual results or events to differ
materially from those described in the forward-looking statements. The company
undertakes no obligation to update publicly any forward-looking statement
whether as a result of new information, future events or otherwise.
- --------------------------------------------------------------------------------
Allegiance Corporation 1997 Annual Report
MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL STATEMENTS 27
Management is responsible for the preparation of the company's consolidated
financial statements and all related information appearing in this report. The
statements and notes conform to generally accepted accounting principles and
include some amounts that are estimates based on available information and
management's judgment of current conditions and circumstances. The company
engaged Price Waterhouse LLP, an independent public accounting firm, to examine
the consolidated financial statements. Their report appears on this page.
To provide reasonable assurance that assets are safeguarded against loss from
unauthorized use or disposition and that accounting records are reliable for
preparing financial statements, management maintains a system of accounting
controls, including an internal audit program. The system of accounting controls
is systematically reviewed and revised to respond to changes in business
conditions, operations and recommendations made by the independent public
accountants and the internal auditors.
The board of directors has an Audit and Public Policy Committee whose members
are not employees of the company. This committee met four times in 1997 with
management, internal auditors and representatives of the company's independent
public accountants to review the company's program of internal controls, audit
plans and results, recommendations of the internal auditors and management's
responses to those recommendations.
/s/ Lester B. Knight /s/ Peter B. McKee /s/ Richard C. Adloff
Lester B. Knight Peter B. McKee Richard C. Adloff
Chairman of the Board Senior Vice President Corporate Vice President
and Chief Executive and Chief Financial and Controller
Officer Officer
REPORT OF INDEPENDENT ACCOUNTANTS
- --------------------------------------------------------------------------------
To the Board of Directors and Stockholders of Allegiance Corporation
In our opinion, the accompanying consolidated balance sheets and the related
consolidated statements of operations, of cash flows and of equity present
fairly, in all material respects, the financial position of Allegiance
Corporation and its subsidiaries at December 31, 1997 and 1996, and the results
of their operations and their cash flows for each of the three years in the
period ended December 31, 1997, in conformity with generally accepted accounting
principles. These financial statements are the responsibility of the company's
management; our responsibility is to express an opinion on these financial
statements based on our audits. We conducted our audits of these statements in
accordance with generally accepted auditing standards which require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for the opinion expressed
above.
As discussed in Note 2 to the consolidated financial statements, the company
changed in 1996 its method of assessing goodwill impairment. We concur with this
change in accounting.
/S/ Price Waterhouse LLP
Price Waterhouse LLP
Chicago, Illinois
January 26, 1998
Allegiance Corporation 1997 Annual Report
28 CONSOLIDATED BALANCE SHEETS
as of December 31 (in millions, except par value and shares) 1997 1996
- ------------------------------------------------------------------------------------------------------------
CURRENT ASSETS Cash and equivalents $ 31.6 $ 22.9
Accounts receivable, net of allowance for
doubtful accounts of $24.1 in 1997 and $26.4 in 1996 510.8 515.1
Notes and other current receivables 17.3 32.4
Inventories
Raw materials 52.3 52.8
Work in progress 44.2 46.4
Finished products 490.4 529.3
---------------------------------------------------------------------------------------
Total inventories 586.9 628.5
Deferred income taxes 97.9 122.8
Prepaid expenses 17.9 13.8
---------------------------------------------------------------------------------------
Total current assets 1,262.4 1,335.5
- ------------------------------------------------------------------------------------------------------------
PROPERTY, PLANT Land 86.8 98.1
AND EQUIPMENT Buildings and leasehold improvements 369.2 397.4
Machinery and equipment 980.1 905.1
Equipment leased or rented to customers 23.5 19.0
Construction in progress 83.9 99.5
---------------------------------------------------------------------------------------
Total property, plant and equipment, at cost 1,543.5 1,519.1
Accumulated depreciation and amortization (748.9) (681.2)
---------------------------------------------------------------------------------------
Net property, plant and equipment 794.6 837.9
- ------------------------------------------------------------------------------------------------------------
OTHER ASSETS Goodwill and other intangibles 553.8 514.5
Other 85.8 111.3
---------------------------------------------------------------------------------------
Total other assets 639.6 625.8
---------------------------------------------------------------------------------------
Total assets $ 2,696.6 $2,799.2
============================================================================================================
CURRENT LIABILITIES Accounts payable, principally trade $ 423.2 $ 436.6
Employee compensation and withholdings 118.2 72.1
Restructuring 26.1 39.3
Property, payroll and other taxes 48.5 31.2
Other 97.6 118.9
---------------------------------------------------------------------------------------
Total accounts payable and current liabilities 713.6 698.1
- ------------------------------------------------------------------------------------------------------------
LONG-TERM DEBT AND LEASE OBLIGATIONS 900.7 1,106.6
- ------------------------------------------------------------------------------------------------------------
DEFERRED INCOME TAXES 99.2 107.4
- ------------------------------------------------------------------------------------------------------------
OTHER NON-CURRENT LIABILITIES 45.9 59.4
- ------------------------------------------------------------------------------------------------------------
EQUITY Common stock, $1 par value, authorized 200,000,000 shares, issued
58,116,000 shares in 1997 and 54,977,000 shares in 1996 58.1 55.0
Additional contributed capital 66.4 1.5
Retained earnings 837.3 769.2
Common stock in treasury, at cost, 749,000 shares in 1997 (25.2) -
Cumulative foreign-currency adjustment 0.6 2.0
---------------------------------------------------------------------------------------
Total equity 937.2 827.7
---------------------------------------------------------------------------------------
Total liabilities and equity $ 2,696.6 $2,799.2
============================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
Allegiance Corporation 1997 Annual Report
CONSOLIDATED STATEMENTS OF OPERATIONS 29
years ended December 31 (in millions, except per share data) 1997 1996 1995
- -----------------------------------------------------------------------------------------------------------------------------------
OPERATIONS Net sales $4,350.8 $4,387.2 $4,921.9
Costs and expenses
Cost of goods sold 3,442.6 3,479.2 3,877.7
Selling, general and administrative expenses 659.0 672.0 749.6
Research and development 9.2 8.1 6.6
Goodwill write-down and
other non-recurring items -- 645.5 76.0
Interest expense 67.5 18.9 --
Goodwill amortization 21.8 32.2 37.8
Benefit curtailment gains -- (35.9) --
Other income 7.7 (4.9) (301.8)
---------------------------------------------------------------------------------------------------------
Total costs and expenses 4,207.8 4,815.1 4,445.9
---------------------------------------------------------------------------------------------------------
Income (loss) before income taxes 143.0 (427.9) 476.0
Income tax expense 52.1 49.8 203.4
---------------------------------------------------------------------------------------------------------
Net income (loss) $ 90.9 $ (477.7) $ 272.6
===================================================================================================================================
PER SHARE DATA Net income (loss) per common share
Basic $ 1.60 $ (8.70) $ 4.97
Diluted 1.56 (8.70) 4.97
===================================================================================================================================
SHARE DATA Average shares outstanding
Basic 56.9 54.9 54.8
Diluted 58.2 54.9 54.8
===================================================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
ALLEGIANCE CORPORATION 1997 ANNUAL REPORT
30 CONSOLIDATED STATEMENTS OF CASH FLOWS
years ended December 31 (in millions, brackets denote cash outflows) 1997 1996 1995
- --------------------------------------------------------------------------------------------------------------------------
CASH FLOW Income (loss) from operations $ 90.9 $ (477.7) $ 272.6
PROVIDED BY Adjustments
OPERATIONS Depreciation and amortization 126.0 145.2 164.6
Deferred income taxes 14.9 (13.7) 50.2
Gain on asset dispositions, net (pretax) (6.0) - (262.5)
Goodwill write-down and other
non-recurring charges - 645.5 76.0
Benefit curtailment gains - (35.9) -
Other 11.0 6.0 5.4
Changes in balance sheet items
Accounts receivable 41.5 (14.7) 73.0
Inventories 57.1 48.1 28.8
Accounts payable and
accrued liabilities 23.8 74.7 (120.2)
Restructuring program payments (27.0) (45.9) (62.0)
Other (4.6) (14.5) 27.4
-------------------------------------------------------------------------------------------------
Cash flow provided by operations 327.6 317.1 253.3
==========================================================================================================================
INVESTMENT Capital expenditures (81.3) (102.5) (111.9)
TRANSACTIONS Acquisitions (60.9) (23.8) (5.4)
Proceeds from asset dispositions 35.2 (11.2) 626.0
-------------------------------------------------------------------------------------------------
Investment transactions, net (107.0) (137.5) 508.7
==========================================================================================================================
FINANCING Issuances of debt 62.3 603.6 -
TRANSACTIONS Redemptions of debt (85.0) - -
Increase (decrease) in debt with maturities
of three months or less, net (188.0) 507.4 -
Common stock cash dividends (22.7) - -
Common stock issued under
Shared Investment Plan 54.8 - -
Common stock issued under
employee benefit plans 13.3 1.7 -
Purchase of common stock in treasury (35.8) - -
Payments to Baxter International Inc. - (1,270.2) (764.0)
Other financing (10.8) - -
-------------------------------------------------------------------------------------------------
Financing transactions, net (211.9) (157.5) (764.0)
==========================================================================================================================
INCREASE (DECREASE) IN CASH AND EQUIVALENTS 8.7 22.1 (2.0)
CASH AND EQUIVALENTS AT BEGINNING OF YEAR 22.9 0.8 2.8
==========================================================================================================================
CASH AND EQUIVALENTS AT END OF YEAR $ 31.6 $ 22.9 $ 0.8
==========================================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
ALLEGIANCE CORPORATION 1997 ANNUAL REPORT
CONSOLIDATED STATEMENTS OF EQUITY 31
years ended December 31 (in millions) 1997 1996 1995
- --------------------------------------------------------------------------------------------------------
COMMON Balance, beginning of year $ 55.0 $ - N/A
STOCK September 30, 1996, distribution of common stock - 54.8
Stock issued under employee benefit plans 0.3 0.2
Stock issued under Shared Investment Plan 2.4 -
Stock issued for acquisitions 0.4 -
------------------------------------------------------------------------------------------
Balance, end of year 58.1 55.0
========================================================================================================
ADDITIONAL Balance, beginning of year 1.5 - N/A
CONTRIBUTED Stock issued under employee benefit plans 2.4 1.5
CAPITAL Stock issued under Shared Investment Plan 52.4 -
Stock issued for acquisitions 10.1 -
------------------------------------------------------------------------------------------
Balance, end of year 66.4 1.5
========================================================================================================
DIVISIONAL Balance, beginning of year - 1,767.5 $2,258.9
RETAINED Net income prior to September 30, 1996 - 117.8 272.6
EARNINGS Payments to Baxter International Inc. - (460.2) (764.0)
September 30, 1996, distribution of common stock - (1,425.1) -
------------------------------------------------------------------------------------------
Balance, end of year - - 1,767.5
========================================================================================================
EQUITY Balance, beginning of year - 810.0 810.0
INVESTMENT Payments to Baxter International Inc. - (810.0) -
OF PARENT ------------------------------------------------------------------------------------------
Balance, end of year - - 810.0
========================================================================================================
RETAINED Balance, beginning of year 769.2 - N/A
EARNINGS September 30, 1996, distribution of common stock - 1,370.3
Common stock dividends declared (22.8) (5.6)
Net loss subsequent to September 30, 1996 - (595.5)
Net income 90.9 -
------------------------------------------------------------------------------------------
Balance, end of year 837.3 769.2
========================================================================================================
COMMON Balance, beginning of year - - N/A
STOCK IN Purchases (35.8) -
TREASURY Stock issued under employee benefit plans 10.6 -
------------------------------------------------------------------------------------------
Balance, end of year (25.2) -
========================================================================================================
CUMULATIVE Balance, beginning of year 2.0 - -
FOREIGN- Currency fluctuations (1.4) 2.0 -
CURRENCY ------------------------------------------------------------------------------------------
ADJUSTMENT Balance, end of year 0.6 2.0 -
========================================================================================================
TOTAL EQUITY $937.2 $ 827.7 $2,577.5
========================================================================================================
n/a - not applicable
The accompanying notes are an integral part of these consolidated financial
statements.
Allegiance Corporation 1997 Annual Report
32 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. DESCRIPTION OF THE BUSINESS
Allegiance Corporation ("Allegiance" or the "company") was incorporated in
Delaware in June 1996. On September 30, 1996 (the "Distribution Date"), Baxter
International Inc. ("Baxter") and its subsidiaries transferred to Allegiance and
its subsidiaries their U.S. health-care distribution business, surgical and
respiratory therapy business and health-care cost-saving business, as well as
certain foreign operations (the "Allegiance Business") in connection with a
spin-off of the Allegiance Business by Baxter. The spin-off occurred on the
Distribution Date through a distribution of Allegiance common stock to Baxter
stockholders (the "Distribution"). The Distribution of approximately 54.8
million shares of Allegiance stock, based on a distribution ratio of one
Allegiance share for each five Baxter shares held, was made to Baxter
stockholders as of the record date of September 26, 1996.
Allegiance operates in a single industry segment as a leading provider of
health-care products and services. Through its nationwide distribution network,
Allegiance distributes a wide offering of medical, surgical and laboratory
products, including its self-manufactured surgical and respiratory therapy
products, to hospitals, doctors' offices, surgery centers, home-care companies,
post-acute-care facilities and other caregivers outside the hospital. Allegiance
also provides integrated cost-saving services to its health-care customers
through inventory-management programs, customized packaging, and various
consulting services.
Allegiance's historical results of operations in 1995 include revenues and
expenses related to certain divested businesses. The Industrial and Life
Sciences division was sold in September 1995, and the diagnostics manufacturing
businesses were sold in December 1994. See Notes 5 and 6 for additional
information.
The following table presents historical financial data for Allegiance
excluding the revenue and expenses associated with divested businesses:
year ended December 31 (in millions) 1995
- -------------------------------------------------------------------------------
Net sales $4,575.0
Costs and expenses
Cost of goods sold 3,624.5
Selling, general and administrative expenses 694.8
Research and development 6.6
Goodwill amortization 36.8
Other income (33.0)
- -------------------------------------------------------------------------------
Total costs and expenses 4,329.7
- -------------------------------------------------------------------------------
Pretax income 245.3
Income tax expense 94.4
- -------------------------------------------------------------------------------
Net income $ 150.9
===============================================================================
Basic and diluted net income per common share $ 2.75
===============================================================================
2. Summary of Significant Accounting Policies
This summary of significant accounting policies is presented to help readers
understand and evaluate the consolidated financial statements. These policies
conform with generally accepted accounting principles and, except for the change
in accounting for goodwill impairment in 1996, have been applied consistently in
all material respects. The preparation of financial statements using generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
BASIS OF PRESENTATION
The accompanying financial statements for periods prior to the Distribution Date
include those assets, liabilities, revenues and expenses directly attributable
to the Allegiance Business. These financial statements were prepared as if
Allegiance had operated as a free-standing entity for the periods presented. The
financial information prior to the Distribution Date, however, does not
necessarily reflect what the financial position and results of operations of
Allegiance would have been had it operated as a stand-alone entity during the
periods covered, and may not be indicative of future operations or financial
position. Certain immaterial reclassifications have been made to the 1996 and
1995 financial statements and related footnotes so they conform to the 1997
presentation.
BASIS OF CONSOLIDATION
The consolidated financial statements include the accounts of Allegiance and its
majority-owned subsidiaries. Certain operations outside the United States and
its territories, which are not material, are included in the consolidated
financial statements on the basis of fiscal years ending November 30.
CASH AND EQUIVALENTS
Cash and equivalents include cash, cash investments and marketable securities
with an original maturity of three months or less. Cash payments for interest
were $67.1 million in 1997 and $7.4 million in 1996. Cash payments for income
taxes were $30.0 million in 1997 and $0.6 million in 1996. Cash payments for
income taxes relating to the Allegiance Business prior to the Distribution Date
were made by Baxter.
Allegiance Corporation 1997 Annual Report
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 33
INVENTORIES
Inventories are stated at the lower of cost (first-in, first-out method) or
market. Market for raw materials is based on replacement cost and for other
inventory classifications on net realizable value. Appropriate consideration is
given to deterioration, obsolescence and other factors in evaluating net
realizable value.
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are stated at cost. Depreciation and amortization
are provided for financial reporting purposes principally on the straight-line
method over the following estimated useful lives: buildings and leasehold
improvements, 20 to 50 years; machinery and other equipment, 3 to 20 years; and
equipment leased or rented to customers, 1 to 5 years. Leasehold improvements
are depreciated over the life of the related facility leases or the asset,
whichever is shorter. Straight-line and accelerated methods of depreciation are
used for income tax purposes.
Depreciation expense was $96.0 million in 1997, $98.8 million in 1996 and
$106.3 million in 1995. Repairs and maintenance expenses were $26.8 million in
1997, $24.2 million in 1996 and $36.4 million in 1995.
GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill represents the excess of cost over the fair value of net assets
acquired and is amortized on a straight-line basis over estimated useful lives
not exceeding 40 years. As part of Baxter, Allegiance followed accounting
policies established by Baxter for its consolidated group. Baxter's policy was
to evaluate the overall recoverability of goodwill using projected undiscounted
cash flows.
Subsequent to the Distribution Date, the market value of Allegiance stock
was substantially below its historical book value. As a result of this market
value and management's expectations that cost-containment efforts in the health-
care industry would continue to produce intense competition among health-care
suppliers, management re-evaluated its accounting policy for goodwill
impairment. In October 1996, the company's board of directors approved the
adoption of a new policy for assessing goodwill impairment based upon a fair
value approach. The company believes that fair value is a preferable method to
assess goodwill as it is a more objective indicator of the company's inherent
value as a separate publicly traded entity and reflects the challenges and
pressures that continue to be a fundamental part of the U.S. health-care system.
This accounting change resulted in a fourth quarter 1996 charge to
operations of $550.0 million and a reduction in 1996 goodwill amortization of
$4.7 million (9 cents per share, basic). This policy change will continue to
reduce goodwill amortization for the next 28 years by $18.9 million annually.
The company computes fair value using the price/earnings ("P/E") multiple
for a group of similar companies. This P/E multiple, calculated using actual
quoted market prices per share and analysts' consensus earnings estimates for
these companies, is applied to management's best estimate of earnings for
Allegiance to arrive at an overall fair value of the company. Based upon
management's assessment, the carrying value of goodwill at December 31, 1997, is
not impaired.
As of December 31, goodwill was $551.4 million in 1997 and $510.7 million
in 1996, net of accumulated amortization of $423.9 million and $400.8 million,
respectively.
Other intangible assets include purchased patents, trademarks and other
identified rights that are amortized on a straight-line basis over their legal
or estimated useful lives, whichever is shorter (not exceeding 20 years). As of
December 31, other intangible assets were $2.4 million in 1997 and $3.8 million
in 1996, net of accumulated amortization of $16.5 million and $18.3 million,
respectively.
INCOME TAXES
Allegiance's operations before the Distribution Date were included in Baxter's
consolidated U.S. federal and state income tax returns and in the tax returns of
certain Baxter foreign subsidiaries. The provision for income taxes prior to the
Distribution Date was determined as if Allegiance had filed separate tax returns
under its structure while part of Baxter. Accordingly, Allegiance's effective
tax rate in 1997 and future years will vary from these historical rates
depending on the company's current legal structure and tax elections. All income
tax expense accrued prior to the Distribution Date was settled with Baxter on a
current basis through Divisional Retained Earnings.
Allegiance has provided for income taxes in accordance with Statement of
Financial Accounting Standards ("SFAS") No. 109, "Accounting for Income Taxes."
DERIVATIVES
Gains and losses related to qualifying hedges are deferred as part of the
carrying amounts of the related assets or liabilities and are ultimately
recognized in income as part of the carrying amounts when the hedged transaction
occurs. Realized and unrealized changes in the fair value of the other
derivative financial instruments are recognized in income in the period in which
the change occurs.
Allegiance Corporation 1997 Annual Report
34 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
STOCK-BASED COMPENSATION
The company accounts for stock-based compensation using the intrinsic value
method prescribed in Accounting Principles Board Opinion No. 25, "Accounting for
Stock Issued to Employees," and related interpretations. Accordingly, the
company recognizes no compensation expense for its fixed stock-option plans or
stock purchase plan. See Note 11.
EARNINGS PER SHARE
Basic net income (loss) per common share is based on the weighted average number
of shares outstanding subsequent to the Distribution, assuming the shares issued
in connection with the Distribution had been issued January 1, 1996. Earnings
per share ("EPS") data presented in 1995 assumes the shares issued at the
Distribution Date were outstanding. In 1997, the company adopted SFAS No. 128,
"Earnings per Share," which requires the presentation of both basic and diluted
EPS. No reconciliation for 1995 is presented because no potentially dilutive
stock plans existed prior to the Distribution.
RECONCILIATION OF BASIC AND DILUTED EPS
years ended December 31 (in millions, except per share data)
Per share
1997 Net income Shares amount
- -----------------------------------------------------------------
Basic EPS $ 90.9 56.9 $ 1.60
Additional shares
assuming exercise of
stock option and stock
purchase plan subscriptions 1.3(a)
- ------------------------------------------------------------------
Diluted EPS $ 90.9 58.2 $ 1.56
==================================================================
Per share
1996 Net loss Shares amount
- ------------------------------------------------------------------
Basic EPS $ (477.7) 54.9 $(8.70)
Additional shares
assuming exercise of
stock option and stock
purchase plan subscriptions ---(b)
- ------------------------------------------------------------------
Diluted EPS $ (477.7) 54.9 $(8.70)
==================================================================
(a) Options to purchase 0.8 million shares at an average price of $29.35 per
share were outstanding during the year ended December 31, 1997, but were not
included in the diluted EPS computation because the exercise price exceeded the
average market price for the period.
(b) Options to purchase 0.8 million shares are excluded from the diluted EPS
computation because they are antidilutive to the net loss per share.
3. Pro Forma Financial Information
The following unaudited pro forma combined statements of operations present the
combined results of Allegiance assuming the transactions effected by the
Distribution and the significant divestitures discussed in Note 1 had been
completed as of January 1, 1995:
years ended December 31
(unaudited, in millions, except per share data) 1996 1995
- ------------------------------------------------------------------------
Net sales $4,386.7 $4,571.1
Costs and expenses
Cost of goods sold 3,481.5 3,624.7
Selling, general and administrative expenses (a) 683.4 706.9
Research and development 8.1 6.6
Goodwill write-down and other
non-recurring items 645.5 -
Interest expense (b) 86.4 90.0
Goodwill amortization 32.2 36.8
Other (income) expense (c) (4.9) 4.3
- ------------------------------------------------------------------------
Total costs and expenses 4,932.2 4,469.3
- ------------------------------------------------------------------------
Pretax income (loss) (545.5) 101.8
Income tax expense (d) 4.2 37.9
- ------------------------------------------------------------------------
Net income (loss) $ (549.7) $ 63.9
========================================================================
Basic and diluted net income (loss)
per common share (e) $ (10.01) $ 1.16
========================================================================
Average number of common
shares outstanding 54.9 54.9
========================================================================
Significant pro forma adjustments (excluding the revenues and expenses
associated with the divested businesses discussed in Note 1) comprise the
following:
(a) Pro forma adjustments of $11.4 million in 1996 and $12.1 million in 1995,
principally reflect certain incremental corporate expenses that are estimated to
have occurred had the company operated on a stand-alone basis, net of the
estimated reduction in expenses related to changes in benefit plans.
(b) Pro forma adjustments of $67.5 million in 1996 and $90.0 million in 1995,
reflect estimated interest expense the company would have incurred on an
estimated $1.2 billion of debt at a weighted average interest rate of 7.5
percent.
(c) Pro forma adjustments of $37.3 million in 1995 reflect non-recurring
payments received related to the transfer of rights under various service
agreements with Alliant Foodservices Inc., to reflect only those ongoing
business operations to be included in the Distribution.
(d) Pro forma adjustments of $45.6 million in 1996 and $56.5 million in 1995
reflect the estimated tax benefit, at statutory rates, for pro forma
adjustments.
(e) Pro forma net income (loss) per common share is computed as if the average
number of common shares of Allegiance stock had been outstanding for the periods
presented.
Allegiance Corporation 1997 Annual Report
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 35
4. Non-Recurring Items
In addition to the goodwill write-down discussed in Note 2, the company incurred
$95.5 million of non-recurring costs in the fourth quarter of 1996. In
conjunction with carving out the Allegiance Business into a separate entity,
management re-evaluated the businesses and product lines in accordance with the
company's strategies. As a result of this evaluation, the company divested and
wrote-down assets of $62.8 million. This was principally a noncash charge that
related to the divestiture of the company's Interwoven business and facility
consolidations.
Other non-recurring charges of $13.2 million were for costs related to the
company's spin-off from Baxter. These costs primarily included corporate
identity, name change and communications costs, as well as certain incremental
compensation costs. In addition, non-recurring charges in the fourth quarter of
1996 included $19.5 million for legal defense costs related to natural rubber
latex litigation cases. See Note 15.
5. Restructuring Programs
Divestitures
Employee and asset Other
(in millions) related costs write-downs costs Total
- --------------------------------------------------------------------------------
Initial restructuring charge $102.5 $ 278.1 $103.4 $ 484.0
Utilization:
Cash (31.0) (22.0) (23.3) (76.3)
Noncash -- (160.2) -- (160.2)
- --------------------------------------------------------------------------------
December 31, 1994 71.5 95.9 80.1 247.5
Utilization:
Cash (28.5) (42.8) (33.2) (104.5)
Noncash -- (66.3) -- (66.3)
Adjustment to reserve -- 76.0 -- 76.0
- --------------------------------------------------------------------------------
December 31, 1995 43.0 62.8 46.9 152.7
Utilization:
Cash (19.0) (15.8) (26.8) (61.6)
Noncash -- (25.0) -- (25.0)
- --------------------------------------------------------------------------------
December 31, 1996 24.0 22.0 20.1 66.1
Utilization:
Cash (10.2) -- (16.8) (27.0)
Noncash -- (5.0) -- (5.0)
- --------------------------------------------------------------------------------
December 31, 1997 $ 13.8 $ 17.0 $ 3.3 $ 34.1
================================================================================
In November 1993, Baxter's board of directors approved a series of strategic
actions designed in part to make the Allegiance Business more efficient and
responsive in addressing the changes occurring in the U.S. health-care system. A
$484.0 million pretax provision was recorded to cover costs associated with
these restructuring initiatives. Since the announcement of the 1993
restructuring program, Allegiance has implemented, or is in the process of
implementing, all of the major strategic actions associated with the
restructuring program, which is expected to be completed by 1999.
Included in the restructuring plan was the intent to divest the diagnostics
manufacturing businesses, and a valuation allowance was established as a
component of the restructuring charge. In December 1994, subject to certain
settlement provisions, the divestiture of these businesses was completed.
Throughout 1995, active discussions took place with the buyer of the diagnostics
businesses related to interpretations of and responsibility for the settlement
provisions contained in the purchase and sale and related agreements. The
divestiture also was significantly complicated by the settlement of a dispute
between the diagnostics manufacturing businesses and one of its major suppliers,
which ultimately led to a lower than expected final valuation of the businesses.
In 1995, settlement negotiations were completed with the buyer of the
diagnostics businesses, and adjustments to the purchase price were finalized,
along with a revision of cost estimates to complete the divestiture. This
resulted in an additional charge of $76.0 million.
Cash outflows pertain primarily to employee-related costs for severance,
outplacement assistance, relocation, implementation teams and facility
consolidations. Since the inception of the restructuring program, approximately
2,500 positions have been eliminated. The remaining expenditures will occur in
1998 and 1999, as implementation team projects and facility closures and
consolidations are completed as planned.
Of the noncash restructuring expenditures, $3.4 million in 1997, $4.4
million in 1996 and $16.0 million in 1995 related to the divestiture of the
diagnostics manufacturing businesses. Noncash spending also included $1.6
million in 1997, $20.6 million in 1996 and $50.3 million in 1995, relating
primarily to fixed asset and inventory write-downs from the closure of
manufacturing facilities and consolidations of certain distribution facilities.
The 1997 restructuring reserve balance consisted substantially of current
reserves. The 1996 restructuring reserve balance consisted of $53.2 million of
current and $12.9 million of non-current reserves.
Allegiance Corporation 1997 Annual Report
36 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
6. Acquisitions and Divestitures
ACQUISITIONS
A component of Allegiance's strategic direction is to make acquisitions that
build on cost-saving and other service offerings, broaden product lines or
expand market coverage. To this end, Allegiance acquired West Hudson & Co. Inc.,
a privately owned health-care consulting firm, on January 2, 1997 for $30.5
million in cash and $10.5 million in stock, with possible contingent payments
through 2000. In addition, the company made individually immaterial acquisitions
of $30.4 million in 1997, $23.8 million in 1996 and $5.4 million in 1995. During
1997, the company exchanged nonmonetary assets with a value of approximately
$10.5 million to acquire an interest in Source Medical Corporation, a new
venture in Canada. All acquisitions were accounted for as purchase transactions.
Had the acquisitions taken place January 1, consolidated results in the year of
acquisition would not have been materially different from reported results.
DIVESTITURES
In 1997, Allegiance sold its investment in MedManagement, L.L.C., generating net
proceeds of approximately $14.3 million. The remaining proceeds from asset
dispositions in 1997 related to the sale of miscellaneous facilities and
divestitures of minor investments deemed inconsistent with Allegiance's
strategic direction.
In 1996, the company paid $11.2 million related primarily to the divestitures
of its Industrial and Life Sciences division ("Industrial") discussed below and
its diagnostics manufacturing businesses discussed in Note 5. In 1995,
Allegiance disposed of several businesses or product lines resulting in a pretax
net gain of $262.5 million (aftertax net gain of $141.0 million). The majority
of this amount related to the $268.1 million gain on the sale of the Industrial
business to VWR Corporation for approximately $400.0 million in cash and $25.0
million in deferred payments. Allegiance continues to supply self-manufactured
products and supplies sold in non-health-care markets to VWR Corporation. In
addition to the approximately $400.0 million of proceeds from the Industrial
sale, the company received $199.9 million in 1995 for the divestiture of its
diagnostics manufacturing businesses. Remaining proceeds in 1995 of $26.1
million related to the disposition of minor investments that were inconsistent
with Allegiance's strategic direction. In most of these transactions, Allegiance
disposed of its entire interest in the investments.
7. Credit Facilities, Long-Term Debt and Lease Obligations
as of December 31 Effective
(in millions, except percentages) interest rate 1997 1996
- --------------------------------------------------------------------------------
Borrowings under credit facilities 5.95% $351.5 $ 562.1
- --------------------------------------------------------------------------------
7.30% notes due 2006 7.39 199.6 199.6
- --------------------------------------------------------------------------------
7.80% debentures due 2016 7.88 149.4 149.4
- --------------------------------------------------------------------------------
7.00% debentures due 2026,
7 year put option in 2003 7.11 199.9 199.9
- --------------------------------------------------------------------------------
Notes and capitalized lease
obligations, due 1998 through 2020 0.5 -
- --------------------------------------------------------------------------------
Total long-term debt and
lease obligations $900.9 $1,111.0
================================================================================
Current portion $ (0.2) $ (4.4)
- --------------------------------------------------------------------------------
Long-term portion $900.7 $1,106.6
================================================================================
The company's unsecured revolving credit agreement, expiring in 2001, provides
for up to an aggregate of $900.0 million in borrowings. As of December 31, $80.0
million in 1997 and $260.0 million in 1996 were outstanding under this facility.
As of December 31, 1996, the company had an additional facility providing for
$150.0 million of borrowings. As of December 31, 1996, no amounts were
outstanding under this facility, which was terminated in 1997. In conjunction
with its credit facilities, the company is required to comply with certain
financial tests and maintain certain leverage ratios.
The company also maintains other short-term credit facilities. At December 31,
$244.2 million in 1997 and $302.1 million in 1996, was outstanding under these
uncommitted facilities. Of the amounts outstanding under all facilities, $324.2
million in 1997 and $557.7 million in 1996 was classified as long-term debt, as
amounts are supported by a long-term credit facility and will continue to be
refinanced. Amounts borrowed under these facilities were used for working
capital requirements and to fund a $1,147.3 million distribution to Baxter in
1996. The company had year-end unamortized debt issuance costs of $4.0 million
in 1997 and $4.5 million in 1996. Such costs are being amortized over the life
of the underlying debt.
Certain facilities and equipment are leased under operating leases, expiring
at various dates. Most of the operating leases contain renewal options. Total
expense for all operating leases was $36.8 million in 1997, $26.0 million in
1996 and $26.4 million in 1995.
Allegiance Corporation 1997 Annual Report
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 37
FUTURE MINIMUM DEBT AND LEASE PAYMENTS
Aggregate debt and
Operating capital lease
as of December 31 (in millions) leases maturities
- --------------------------------------------------------------------------------
1998 $ 32.0 $ 0.2
1999 27.0 0.2
2000 22.8 0.1
2001 15.2 351.5
2002 13.2 -
Thereafter 24.2 550.0
- --------------------------------------------------------------------------------
Total obligations and commitments $134.4 $902.0
================================================================================
Amounts representing interest, discounts,
premiums and deferred financing costs $ 1.1
- --------------------------------------------------------------------------------
Present value of long-term debt and
lease obligations $900.9
================================================================================
8. Financial Instruments and Risk Management
CONCENTRATIONS OF CREDIT RISK
The company provides credit, in the normal course of business, to hospitals,
private and government institutions, health-care agencies, insurance agencies
and doctors' offices. The company performs ongoing credit evaluations of its
customers and maintains reserves for credit losses which have been within the
range of management's allowance for doubtful accounts.
The company actively evaluates the creditworthiness of the financial
institutions which are counterparties to derivative financial instruments, and
it does not expect any counterparties to fail to meet their obligations. The
credit exposure of the company's derivative financial instruments is represented
by the fair value of contracts with a favorable fair value at December 31, 1997.
FINANCIAL INSTRUMENT USE--SUBSEQUENT TO DISTRIBUTION DATE
Allegiance uses commodity contracts to hedge raw materials expected to be
denominated in foreign currency. These contracts generally cover a one-year
period and all gains and losses are deferred and recognized in cost of goods
sold with the underlying product costs. At December 31, the related notional
amounts of such contracts were $9.2 million in 1997 and $22.1 million in 1996.
These notional amounts do not represent amounts exchanged by the parties; rather
they are used as the basis to calculate the amounts due under the contracts.
These contracts qualify as hedges for accounting purposes in accordance with the
criteria established in SFAS No. 80 "Accounting for Futures Contracts." Cash
flows resulting from these commodity contracts are classified in the same
category as the items being hedged.
The company manages the impact of interest rate changes on earnings, cash
flows and borrowings to maintain fixed-rate debt as a percentage of total debt
between a minimum and maximum percentage. In 1997 and 1996, the company
evaluated its interest rate exposures and concluded it was not beneficial to use
financial instruments to hedge its interest positions.
The company uses financial instruments, as needed, to manage cash flow
volatility and earnings fluctuations associated with changes in foreign-exchange
rates. At December 31, 1997, the company had foreign-currency forward and option
contracts outstanding that hedged a portion of anticipated production costs
expected to be denominated in the Malaysian ringgit. The related amounts of
these contracts were $23.2 million for the forward contracts and $17.7 million
for the option contracts at December 31, 1997. The contracts settle monthly
through June 1998. The company recognizes realized and unrealized gains and
losses on these contracts in income in the period in which the change occurs
because the contracts are not qualifying hedges for accounting purposes. Net
expense during 1997 was $11.6 million. The company did not use derivative
instruments to manage its foreign-exchange exposures during 1996. Allegiance
does not use financial instruments for trading purposes.
FINANCIAL INSTRUMENT USE--PRIOR TO DISTRIBUTION DATE
Allegiance was considered in Baxter's overall risk management strategy prior to
the Distribution Date. As part of this strategy, Baxter used certain financial
instruments to reduce its exposure to adverse movements in foreign-exchange
rates, interest rates and certain commodity prices. The strategies of Baxter did
not utilize financial instruments for trading purposes.
Prior to the Distribution Date, Baxter allocated to Allegiance the income and
expense associated with certain option contracts used to hedge anticipated costs
of production expected to be denominated in foreign currencies. The terms of
these financial instruments were less than one year. Allocated net expense and
the related notional amounts for these options were immaterial in all years
presented.
FAIR VALUES OF FINANCIAL INSTRUMENTS
Carrying Approximate
as of December 31, 1997 (in millions) value fair value
- -------------------------------------------------------------------------------
Short-term borrowings classified as long-term $351.5 $351.5
Other long-term debt and lease obligations 549.4 577.8
Commodity hedges - (3.4)
Foreign-currency forward contracts - (7.8)
Foreign-currency option contracts - 2.2
===============================================================================
Allegiance Corporation 1997 Annual Report
38 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The carrying values of current assets and liabilities, including short-term
borrowings, which have been classified as long-term, approximated their fair
values at December 31, 1997 and 1996 due to their short-term maturities. The
carrying values of long-term borrowings and commodity hedges approximated their
fair values at December 31, 1996. The fair values of all other items noted in
the above table are based on quoted market prices for the same or similar
instruments.
Investments in affiliates are accounted for by both the cost and equity
methods and pertain to several minor investments in companies for which fair
values are determined by quoted market prices and others for which fair values
are not readily available, but are believed to approximate carrying amounts.
9. Related Party Transactions
Prior to the Distribution Date, Baxter provided to Allegiance certain legal,
treasury, insurance and administrative services. Charges for these services were
based on actual costs incurred by Baxter. In addition, Allegiance was the
primary distributor of Baxter's intravenous solutions, cardiovascular devices
and other products in the United States and also provided other services to
Baxter. Negotiated fees for these distribution services were generally under the
same terms and conditions granted to independent third parties. Additionally,
these fees were not materially different than the terms of the distribution
agreement subsequent to the Distribution. A summary of related party
transactions, all of which were with Baxter or Baxter affiliates, is shown in
the table below:
From
Jan. 1 to
(in millions) Sept. 30, 1996 1995
- -----------------------------------------------------------
Allegiance provided:
Distribution services to Baxter
in the United States $160.4 $213.7
Administrative services to Baxter 18.9 25.2
Allegiance received:
Administrative services
from Baxter $ 36.2 $ 48.3
International distribution
services from Baxter 19.4 25.8
===========================================================
Management believes the pre-Distribution Date basis used to allocate corporate
services was reasonable. However, the terms of these transactions may differ
from those that would have resulted from transactions among unrelated parties.
Prior to the Distribution Date, Allegiance participated in a centralized cash-
management program administered by Baxter. Short-term advances from Baxter or
excess cash sent to Baxter were treated as adjustments to Divisional Retained
Earnings through the Distribution Date. No interest was charged on this balance.
Effective on the Distribution Date, Baxter and Allegiance entered into a
series of administrative-services agreements under which Baxter and Allegiance
would continue to provide, for a specified period of time, certain
administrative services that each entity historically had provided to the other.
These agreements require both parties to pay each other a fee that approximates
the actual costs of these services. Additionally, Allegiance has continuing
significant relationships with Baxter as a distributor, agent, customer and
supplier for an array of health-care products and services.
10. Preferred Stock
The board of directors has authorized two million shares of $.01 par value
preferred stock that can be issued in series with varying terms as determined by
the board of directors. No shares of preferred stock have been issued.
PREFERRED STOCK PURCHASE RIGHTS
In September 1996, common stockholders received a dividend of one preferred
stock purchase right (collectively, the "Rights") for each share of common stock
held of record. Each Right entitles the registered holder to purchase from the
company one one-hundredth of a share of Series A Junior Participating Preferred
Stock for $65 (subject to adjustment). The Rights will become exercisable (and
transferable apart from the common stock) on the earlier of (1) 10 days
following a public announcement that a person or group has acquired or obtained
the right to acquire 15 percent or more of the common stock, or (2) 10 business
days following the commencement of an offer to acquire 15 percent or more of
Allegiance common stock.
If, after the Rights become exercisable, any person or group (the "Acquirer")
acquires 15 percent or more of the common stock (except pursuant to an offer for
all outstanding shares of common stock which the independent directors determine
to be fair to and otherwise in the best interests of the company and its
stockholders) each Right may be exercised for common stock (or, in certain
circumstances, cash, other property or securities) having a value of $130 or
equal to two times the exercise price of the Right, if adjusted. In specified
circum-
Allegiance Corporation 1997 Annual Report
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 39
stances, each Right may be exercised for common stock of an acquiring entity
having a value of $130. All Rights held by the Acquirer will be null and void.
The company may generally redeem the Rights at a price of $.01 per Right at any
time until the Rights become transferable apart from the common stock. The
Rights will expire at the close of business on September 30, 2006, unless
redeemed earlier.
11. Common Stock
EMPLOYEE STOCK PURCHASE PLAN
The company has an employee stock purchase plan under which the sale of two
million shares of its common stock has been authorized. The purchase price is
the lower of 85 percent of the closing market price on the date of subscription
or 85 percent of the closing market price on the date of purchase. Under this
plan, the company sold to employees 545,673 shares at an average price per share
of $17.88 in 1997 and 93,159 shares at an average price per share of $15.66 in
1996. At December 31, 1997 and 1996, subscriptions of 576,492 shares and 888,661
shares were outstanding. The weighted average fair value for each purchase right
was $7.13 in 1997 and $4.79 in 1996.
INCENTIVE COMPENSATION PLANS
The company has various incentive plans for employees under which the grant of
approximately 9.7 million shares of its common stock has been authorized. At
December 31, 1997, there were approximately 264,000 shares remaining to be
issued under this authorization.
The company granted restricted common stock under this authorization in the
amount of 86,203 shares in October 1996 and 4,047 shares in August 1997 to
provide compensation to selected employees. All outstanding restricted shares
are subject to future employment and vest two years from the grant date. In
1997, 1,727 shares were forfeited. There has been no other activity related to
restricted shares.
Various stock-option plans are also included under this authorization. Other
than the Shared Investment Plan discussed below, all outstanding options under
these plans have been granted at 100 percent of market value on the dates of
grant, have a 10 year term and vest equally over three years from the grant
date. The average remaining life of options outstanding at December 31, 1997 was
8.9 years. The exercise prices range from $18.38 to $29.38.
On May 2, 1997, the company received $54.8 million in cash from 141 members of
Allegiance's management who purchased approximately 2.4 million shares of the
company's stock. The company granted one-day options for the shares, which were
immediately exercised, from the approximately 9.7 million share authorization
discussed above. This Shared Investment Plan was designed to align management
and stockholder interests. Under terms of the voluntary program, Allegiance
managers used personal full-recourse loans to purchase the newly issued shares
at the closing price per share on May 2, 1997 of $23 1/4. The loans, borrowed
from several banks, are at market interest rates and are the personal
obligations of the participants. Allegiance has agreed to guarantee repayment to
the banks in the event of default by a participant. Allegiance may take all
actions necessary to obtain full reimbursement from the participant for amounts
paid by Allegiance, if any, to the banks in the future under its guarantee.
FIXED STOCK-OPTION TRANSACTIONS
for the years ended December 31
Weighted
average
1997 Shares exercise price
- ----------------------------------------------------------------------
Beginning of year 6,417,601 $19.96
Granted 3,493,770 24.78
Exercised (2,503,995) 23.07
Forfeited (580,441) 20.56
- ----------------------------------------------------------------------
Stock options outstanding, end of year 6,826,935 $21.23
- ----------------------------------------------------------------------
Stock options exercisable, end of year 1,878,278 $19.93
- ----------------------------------------------------------------------
Weighted average fair value of each
option granted during the year $11.99
======================================================================
Weighted
average
1996 Shares exercise price
- ----------------------------------------------------------------------
Inception of plans -- --
Granted 6,459,329 $19.95
Exercised -- --
Forfeited (41,728) 18.38
- ----------------------------------------------------------------------
Stock options outstanding, end of year 6,417,601 $19.96
- ----------------------------------------------------------------------
Stock options exercisable, end of year -- --
- ----------------------------------------------------------------------
Weighted average fair value of each
option granted during the year $ 7.83
======================================================================
Allegiance Corporation 1997 Annual Report
40 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SFAS NO. 123
No compensation cost has been recognized for the stock-option or stock purchase
plans noted above. Had compensation cost been determined based on the fair value
at the date of grant in accordance with the provisions of SFAS No. 123,
"Accounting for Stock-Based Compensation:" net income would have been $75.7
million in 1997; basic and diluted net income per share would have been $1.33
and $1.30, respectively, in 1997; net loss for 1996 would have been $480.5
million; and basic and diluted net loss per share would have been $8.75 in 1996.
The fair value of each option-grant is estimated on the date of grant using the
Black-Scholes option-pricing model and the following assumptions:
Weighted Average Assumptions
years ended December 31 1997 1996
- --------------------------------------------------------------------------------------------
Dividend yield 1.13% -- 1.45% 1.45%
Expected volatility 28.8% -- 62.8% 29.8% -- 32.9%
Risk-free interest rate 4.9% -- 6.6% 5.1% -- 6.5%
Expected life 1 month-7 years 1 month-7 years
============================================================================================
NON-EMPLOYEE DIRECTOR PROGRAM
The company granted 94,998 shares in October 1996 to non-employee directors.
These options, granted at an exercise price of $18.38, were granted at 100
percent of market value on the date of grant, have a 10-year term and vest in
May 1998. There has been no activity related to these shares. The fair value of
each grant is estimated at $7.29.
OTHER
On November 6, 1997, Allegiance's board of directors authorized the company to
repurchase up to 3 million shares of the company's common stock. Allegiance
repurchased 1 million shares ($35.8 million) in 1997 and is authorized to
repurchase the remaining 2 million shares in a systematic manner over
approximately two years. The stock is held in treasury and will be used in the
administration of the company's employee stock purchase plan and other benefit
programs.
12. Retirement and Other Benefit Programs
Most U.S. employees are eligible to participate in a qualified 401(k) plan.
Participants may contribute to the plan up to 12 percent of their base-pay
earnings during the year (limited in 1997 to $9,500 per individual), and
Allegiance matches participants' contributions, up to 3 percent of base-pay
earnings. Matching contributions made by Allegiance were $7.8 million in 1997,
$9.4 million in 1996 and $11.4 million in 1995.
In addition to the matching contribution discussed above, eligible employees
at December 31, 1997, received a contribution to their respective fixed
retirement accounts in an amount equal to 3 percent of their base-pay earnings
during the year. Expense related to this benefit in 1997 was $10.6 million.
Contributions in excess of 3 percent can be made at management's discretion. No
additional contributions were made for 1997.
Certain employees as of December 31, 1997, who participated in Baxter-
sponsored defined benefit plans prior to the Distribution Date are eligible to
receive a contribution to their respective transition retirement account in an
amount ranging from 2 to 8 percent of their base-pay earnings during the year,
depending on benefit service points. This transitional benefit will be provided
to eligible employees through 2003. Expense related to this benefit in 1997 was
$5.0 million.
The liability associated with post-employment benefits such as disability-
related and workers' compensation payments was $18.8 million and $17.5 million
at December 31, 1997 and 1996, respectively.
RETIREMENT AND OTHER BENEFIT PROGRAMS--
PRIOR TO DISTRIBUTION DATE ONLY
Allegiance participated in Baxter-sponsored non-contributory, defined benefit
pension plans covering substantially all domestic employees as well as Baxter-
sponsored contributory health-care and life-insurance benefit plans for
substantially all domestic retired employees. Effective on the Distribution
Date, Allegiance did not replace these Baxter plans. The pension liability
related to Allegiance employees' service prior to the Distribution Date remained
with Baxter. Additionally, the post-retirement liabilities for Allegiance
employees who retired before the Distribution Date also remained with Baxter. As
a result, Allegiance recognized curtailment gains of $35.9 million related to
these plans in the third quarter of 1996.
Allegiance Corporation 1997 Annual Report
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 41
Pension expense associated with the Baxter-sponsored plans prior to being
frozen was $17.2 million for the nine months ended September 30, 1996, and $17.2
million for the year ended December 31, 1995.
Expense associated with retiree benefits prior to the Distribution Date was
$5.0 million for the nine months ended September 30, 1996, and $9.4 million in
1995.
13. Other (Income) Expense
years ended December 31 (in millions) 1997 1996 1995
- -----------------------------------------------------------------
Asset dispositions, net $(7.7) $ - $(262.5)
Foreign exchange 6.4 1.0 0.3
Foreign-currency hedging contracts 11.6 - -
Other (2.6) (5.9) (39.6)
- -----------------------------------------------------------------
Total other (income) expense $ 7.7 $(4.9) $(301.8)
=================================================================
14. Income Taxes
INCOME (LOSS) BEFORE INCOME TAX EXPENSE BY CATEGORY
years ended December 31 (in millions) 1997 1996 1995
- -----------------------------------------------------------------
United States $103.4 $(491.9) $433.9
International 39.6 64.0 42.1
- -----------------------------------------------------------------
Income (loss) before
income taxes $143.0 $(427.9) $476.0
=================================================================
INCOME TAX EXPENSE BY CATEGORY
years ended December 31 (in millions) 1997 1996 1995
- -----------------------------------------------------------------
Current
U.S.
Federal $28.3 $ 48.6 $124.1
State and local 7.8 11.4 34.2
International 1.0 3.5 (5.1)
- -----------------------------------------------------------------
Current income tax expense 37.1 63.5 153.2
- -----------------------------------------------------------------
Deferred
U.S.
Federal 14.2 (9.4) 38.0
State and local 3.8 (1.4) 8.4
International (3.0) (2.9) 3.8
- -----------------------------------------------------------------
Deferred income tax expense (benefit) 15.0 (13.7) 50.2
- -----------------------------------------------------------------
Total income tax expense $52.1 $ 49.8 $203.4
=================================================================
Income tax expense prior to the Distribution Date was calculated as if
Allegiance had been a stand-alone entity.
DEFERRED TAX ASSETS AND LIABILITIES
years ended December 31 (in millions) 1997 1996 1995
- ---------------------------------------------------------------
Deferred tax assets
Accrued expenses $102.4 $ 93.8 $ 70.0
Restructuring and
non-recurring costs 20.0 62.4 56.9
Other 1.4 - 0.1
- ---------------------------------------------------------------
Total deferred tax assets 123.8 156.2 127.0
- ---------------------------------------------------------------
Deferred tax liabilities
Asset-basis differences 113.2 125.8 106.7
Other - 4.8 1.0
- ---------------------------------------------------------------
Total deferred tax liabilities 113.2 130.6 107.7
- ---------------------------------------------------------------
Net deferred tax assets $ 10.6 $ 25.6 $ 19.3
===============================================================
In 1996, $7.4 million of deferred tax assets were transferred
to Baxter, related primarily to spin-off costs assumed by Baxter.
Under a tax-sharing agreement with Baxter, Allegiance will pay for increases
and be reimbursed for decreases to the net deferred tax assets transferred on
the Distribution Date. Such increases or decreases may result from audit
adjustments to Baxter's prior period tax returns.
RECONCILIATION OF INCOME TAX EXPENSE (BENEFIT)
years ended December 31 (in millions) 1997 1996 1995
- -------------------------------------------------------------------
Income tax expense (benefit)
at statutory rate $ 50.0 $(149.8) $166.4
Tax-exempt operations (15.7) (19.6) (17.4)
Nondeductible goodwill
and non-recurring costs 6.2 213.5 28.1
State and local taxes 7.6 6.5 27.0
Foreign tax expense (0.2) (2.0) (0.8)
Valuation allowance for losses
in unconsolidated subs 3.1 - -
Other factors 1.1 1.2 0.1
- -------------------------------------------------------------------
Income tax expense $ 52.1 $ 49.8 $203.4
===================================================================
The company has manufacturing operations outside the United States that benefit
from reductions in local tax rates under tax incentives that will continue at
least through 1998. U.S. federal income taxes, net of available foreign tax
credits, on unremitted foreign earnings would have been approximately $52.3
million and $36.4 million as of December 31, 1997 and 1996.
Allegiance Corporation 1997 Annual Report
42 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
15. Legal Proceedings
Upon the Distribution, Allegiance assumed the defense of litigation involving
claims related to the Allegiance Business, including certain claims of alleged
personal injuries as a result of exposure to natural rubber latex gloves
described below. Allegiance will be defending and indemnifying Baxter Healthcare
Corporation ("BHC"), as contemplated by the agreements between Baxter and
Allegiance, for all expenses and potential liabilities associated with claims
pertaining to this litigation. It is expected that Allegiance will be named as a
defendant in future litigation and may be added as a defendant in existing
litigation.
BHC was one of 10 defendants named in a purported class action filed in August
1993, Kennedy, et al., v. Baxter Healthcare Corporation, et al., (Sup. Ct.,
Sacramento Co., Cal., #535632), on behalf of all medical and dental personnel in
the State of California who allegedly suffered allergic reactions to natural
rubber latex gloves and other protective equipment or who allegedly have been
exposed to natural rubber latex products. The case alleged that users of various
natural rubber latex products, including medical gloves made and sold by BHC and
other manufacturers, suffered allergic reactions to the products ranging from
skin irritation to systemic anaphylaxis. The Court granted defendants' demurrer
to the class action allegations. On February 29, 1996, the California Appellate
Court upheld the trial court's ruling and the case was dismissed. On April 8,
1994, a similar purported class action, Green, et al., v. Baxter Healthcare
Corporation, et al., (Cir. Ct., Milwaukee Co., WI, 94CV004977), was filed
against BHC and three other defendants. The class action allegations have been
withdrawn, but additional plaintiffs added individual claims. On July 1, 1996,
BHC was served with a similar purported class action, Wolf v. Baxter Healthcare
Corp., et al., (Circuit Court, Wayne County, MI, 96-617844NP). BHC is the only
named defendant in that suit. On January 3, 1997, BHC was served with a similar,
nationwide proposed class action, Murray, et al., v. Baxter Healthcare
Corporation, et al., (U.S.D.C. Southern District of Indiana, IP96-1889C). BHC
and three other companies are defendants. On April 11, 1997, a similar proposed
statewide class action, Delpit, et al. v. Ansell, Inc., et al., (U.S.D.C.
Eastern District of Louisiana, 97-1112), was filed on behalf of users of latex
gloves in the State of Louisiana. BHC and five other companies are defendants.
On April 29, 1997, another similar proposed state-wide class action, Cowart, et.
al. v. Ansell, Inc., et. al., (Civil District Court, Parish of Orleans, 97-
7237), was filed on behalf of users of latex gloves. Baxter International Inc.
and three other companies are defendants. On November 5, 1997, plaintiffs in
each of these cases stipulated to the dismissal of the class claims. On August
8, 1997, BHC was served with a writ of summons in a case styled, Swartz v. Ach,
Inc., et al., (Court of Common Pleas of Jefferson County, Pennsylvania Civil
Division, No.656-1997 C.D.) which purports to be a similar class action directed
against manufacturers, distributors and sellers of natural rubber products. On
October 9, 1996, the plaintiff in a case pending in federal court filed a
petition with the Judicial Panel Multi District Litigation, In Re Latex Gloves
Products Liability Litigation, (MDL Docket No. 1148), seeking to transfer and
consolidate the cases involving claims related to natural rubber latex gloves
pending in federal court for pretrial proceedings and/or trial. On February 26,
1997, the Panel granted the petition and ordered all cases pending in federal
court to be transferred to the Eastern District of Pennsylvania for coordinated
or consolidated pretrial proceedings. As of March 4, 1998, there are an
additional 200 active lawsuits and one claim involving BHC and/or the company
containing similar allegations of sensitization to natural rubber latex
products. Allegiance intends to vigorously defend against these actions. Since
none of these cases has proceeded to a hearing on the merits, Allegiance is
unable to evaluate the extent of any potential liability, and unable to estimate
any potential loss.
Because of the increase in claims filed and the ongoing defense costs that
will be incurred, the company believes it is probable that Allegiance will incur
significant expenses related to the defense of cases involving natural rubber
latex gloves. During the fourth quarter of 1996, the company recorded a charge
of $19.5 million to provide the minimum amount of the potential range of defense
costs expected to be incurred related to existing cases. On an ongoing basis,
the company assesses the adequacy of reserves and provides the minimum amount of
this potential range.
Allegiance believes a substantial portion of any potential liability and
remaining defense costs related to natural rubber latex gloves cases and claims
will be covered by insurance, subject to self-insurance retentions, exclusions,
conditions, coverage gaps, policy limits and insurer solvency. In 1996, Baxter
notified
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 43
its insurance companies that it believes these cases and claims are covered by
Baxter's insurance. Most of the insurers have reserved their rights (i.e.,
neither admitted nor denied coverage), and may attempt to reserve in the future,
the right to deny coverage, in whole or in part, due to differing theories
regarding, among other things, the applicability of coverage and when coverage
may attach. Upon resolution of any of the uncertainties concerning these cases,
the company may incur charges in excess of presently established reserves. Based
upon the advice of counsel, it is not expected that the outcome of these matters
will have a material adverse effect on Allegiance's overall business, cash flow,
results of operations or financial condition.
Under the U.S. Superfund statute and many state laws, generators of hazardous
waste sent to a disposal or recycling site are liable for cleanup of the site if
contaminants from that property later leak into the environment. The law
provides that potentially responsible parties may be held jointly and severally
liable for the cost of investigating and remediating a site. This liability
applies to the generator even if the waste was handled by a contractor in full
compliance with the law.
As of December 31, 1997, BHC had been identified as a potentially responsible
party for cleanup costs at ten hazardous waste sites, for which Allegiance has
assumed responsibility. Allegiance's largest assumed exposure is at the Thermo-
Chem site in Muskegon, Michigan. Allegiance expects the total cleanup costs for
this site to be between $44.0 million and $65.0 million, of which Allegiance's
share would be approximately $5.4 million. This amount, net of payments of
approximately $1.6 million, has been accrued and is reflected in Allegiance's
consolidated financial statements. The estimated exposure for the remaining nine
sites is approximately $3.8 million, which has been accrued and reflected in
Allegiance's consolidated financial statements.
The company is a defendant in, or has assumed the defense of, a number of
other claims, investigations and lawsuits. Upon resolution of any of these
uncertainties, the company may incur charges in excess of presently established
reserves. Based on the advice of counsel, management does not believe the
outcome of these matters or the environmental matters, individually or in the
aggregate, will have a material adverse effect on Allegiance's overall business,
cash flow, results of operations or financial condition.
16. Industry and Geographic Information
Most of Allegiance's international sales are in Canada, France and Germany. The
company has international manufacturing operations in Malaysia, Mexico, France,
Malta and the Netherlands. The majority of raw materials used to manufacture
natural rubber latex gloves is found in Malaysia. None of these geographic
locations represents 10 percent or more of the company's net sales or
identifiable assets.
For the last three years, sales to customers that are members of two large
hospital buying groups, Premier, Inc. ("Premier") and VHA Inc. ("VHA"), as a
percentage of total sales, were 28 percent and 20 percent, respectively, in
1997, 27 percent and 20 percent, respectively, in 1996, and 27 percent and 16
percent, respectively, in 1995. Premier and VHA each comprise a group of health-
care organizations that benefit from the pricing and other benefits available to
members of the group. Certain members of each group are free to purchase from
vendors of their choice. Although the loss of the relationship with either group
could have a significant impact on sales to members of the group, the loss of
such group would not necessarily mean the loss of sales from all members of the
group.
Allegiance Corporation 1997 Annual Report
44 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
17. Quarterly Financial Results and Market for the Company's Stock (Unaudited)
First Second Third Fourth Total
(unaudited, in millions, except per share data) quarter quarter quarter quarter year
- ----------------------------------------------------------------------------------------------------
1997
Net sales $1,055.9 $1,075.0 $1,083.3 $1,136.6 $4,350.8
Gross profit 219.8 223.4 226.5 238.5 908.2
Net income 21.0 22.0 23.0 24.9 90.9
Per common share:
Net income
Basic 0.38 0.39 0.40 0.43 1.60
Diluted 0.37 0.38 0.39 0.42 1.56
Dividends 0.10 0.10 0.10 0.10 0.40
Market price
High 26.38 28.38 31.63 35.44 35.44
Low 22.13 20.00 26.44 27.50 20.00
====================================================================================================
1996
Net sales $1,115.0 $1,086.1 $1,094.2 $1,091.9 $4,387.2
Gross profit 225.7 229.1 230.7 222.5 908.0
Net income (loss)/(1)/ 30.6 26.7 60.5 (595.5) (477.7)
Per common share:
Net income (loss)/(1) (2)/
Basic 0.56 0.49 1.10 (10.85) (8.70)
Diluted 0.56 0.49 1.10 (10.85) (8.70)
Dividends n/a n/a n/a 0.10 0.10
Market price
High/(3)/ n/a n/a 18.63 27.88 27.88
Low/(3)/ n/a n/a 16.25 17.00 16.25
====================================================================================================
n/a - not applicable
(1) Net loss for the fourth quarter 1996 includes non-recurring pretax charges
of $550.0 million for the write-down of goodwill and $95.5 million
primarily for facility consolidations and other asset write-downs.
(2) Earnings per share data through September 30, 1996, assume the shares
issued in connection with the spin-off from Baxter International Inc. were
outstanding.
(3) Allegiance stock traded on a "when issued" basis from September 24, 1996,
to September 30, 1996.
Allegiance common stock is listed on the New York Stock Exchange and the Chicago
Stock Exchange. The New York Stock Exchange is the principal market on which the
company's common stock is traded. At January 31, 1998, there were approximately
43,925 holders of record of the company's common stock.
Allegiance Corporation 1997 Annual Report
FIVE-YEAR SUMMARY OF SELECTED FINANCIAL DATA 45
years ended December 31 1997 1996/(1)/ 1995/(2)/ 1994/(2)/ 1993/(2)(3)/
- -------------------------------------------------------------------------------------------------------------------------------
OPERATIONS Net sales $4,350.8 $4,387.2 $4,921.9 $5,108.6 $5,019.3
(in millions) Net income (loss) 90.9 (477.7) 272.6 214.9 (68.4)
Depreciation and amortization 126.0 145.2 164.6 222.8 221.0
- -------------------------------------------------------------------------------------------------------------------------------
CAPITAL EMPLOYED Working capital $ 548.8 $ 637.4 $ 679.7 $1,054.9 $ 928.1
(in millions) Capital expenditures 81.3 102.5 111.9 122.4 273.1
Total assets 2,696.6 2,799.2 3,443.7 4,031.4 4,576.2
Long-term debt and lease obligations 900.7 1,106.6 - - -
- -------------------------------------------------------------------------------------------------------------------------------
PER COMMON Average number of common shares
SHARE/(4)/ outstanding (in millions)
Basic 56.9 54.9 54.8 54.8 54.8
Diluted 58.2 54.9 54.8 54.8 54.8
Net income (loss)
Basic $ 1.60 $ (8.70) $ 4.97 $ 3.92 $ (1.25)
Diluted 1.56 (8.70) 4.97 3.92 (1.25)
Cash dividends declared 0.40 0.10 n/a n/a n/a
Market price--high 35.44 27.88 n/a n/a n/a
Market price--low 20.00 16.25 n/a n/a n/a
- -------------------------------------------------------------------------------------------------------------------------------
PRODUCTIVITY Employees at year-end 19,800 20,700 21,300 21,100 26,900
MEASURES Sales per year-end employee $219,737 $211,942 $231,075 $242,114 $186,591
Net income (loss) per employee 4,591 (23,077) 12,798 10,185 (2,543)
- -------------------------------------------------------------------------------------------------------------------------------
FINANCIAL RETURNS Net income (loss) as a percentage of sales 2.1% (10.9%) 5.5% 4.2% (1.4%)
AND STATISTICS Long-term debt as a percentage of total
year-end capital 49.0 57.2 - - -
===============================================================================================================================
n/a--not applicable
(1) Net loss for 1996 includes non-recurring pretax charges of $550.0 million
for the write-down of goodwill and $95.5 million primarily for facility
consolidations and other asset write-downs.
(2) Data includes certain businesses that were divested in 1994 and 1995.
(3) Net loss includes a provision for restructuring charges of a pretax amount
of $484.0 million.
(4) Earnings per share data prior to 1996 assume the shares issued in
connection with the spin-off from Baxter International Inc. were
outstanding.
Allegiance Corporation 1997 Annual Report